Efficacy evaluation of digestive in patients who underwent gastrectomy for gastric cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0008756

Enrollment

240

Registered

2023-09-01

Start date

2023-09-11

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : - Prokinetics group (n=80) : Gamotec (mosapride) 15mg qd x 4 weeks - Digestive enzyme group (n=80): Phazyme 1T tid x 4 weeks - Control group (n=80): no medication

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients 19 years of age or older 2. Patients who underwent gastrectomy for gastric cancer 3. Patients who do not need adjuvant chemotherapy and under follow- up 4. Patient having no abnormal finding in endoscopic examination at 3 months (±4 weeks), postoperatively 5. Patients having postprandial satiety or early satiety for more than 3 days per week at 3 months (±4 weeks) after surgery (postprandial distress syndrome of ROMA IV classification, postprandial distress syndrome

Exclusion criteria

Exclusion criteria: 1. Vulnerable subjects (pregnant patients, those lacking communication ability, etc.) 2. Patients who have taken drugs classified as digestive agents within 7 days from the time of registration 3. Patients taking drugs that affect digestive function an evaluation (anti-cancer drugs, adrenal cortical hormone drugs, anti-inflammatory drugs, etc.) 4. Patients with genetic problems of galactose intolerance 5. Patients judged unsuitable for participation in this study by the researcher

Design outcomes

Primary

Measure	Time frame
symptom relief rate	—

Secondary

Measure	Time frame
quality of life, compliance, adverse effect	—

Countries

Korea, Republic of

Contacts

Public ContactChung Sim Kwon

National Cancer Center

74519@ncc.re.kr+82-31-920-0069

Outcome results